Evidence map›Paper›PMID 27325914›Full record

ArticleFuture virology2016

Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.

Maaike Everts, Mark J Suto, George R Painter, Richard J Whitley

Abstract read
In one paragraph

Article in Future virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maaike EvertsSchool of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Mark J SutoSouthern Research Institute, Birmingham, AL 35205, USA.
George R PainterDrug Innovation Ventures at Emory, LLC (DRIVE) & the Emory University School of Medicine, Atlanta, GA 30309, USA.
Richard J WhitleySchool of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.

Funding

Screening CoreU19AI109680 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2014 to 2018
$34.9M
NIAID NIH HHS U19 AI109680
6 · The paper itself

Abstract

Viral infections, such as Ebola, severe acute respiratory syndrome/Middle East respiratory syndrome and West Nile virus have emerged as a serious health threat with no effective therapies. These infections have little commercial potential and are not a high priority for the pharmaceutical industry. However, the academic community has been active in this area for many years. The challenge is how to take this academic virology knowledge into a drug discovery and development domain. One approach is the use of consortia and public-private partnerships

Indexed as

antiviralscollaborationconsortiadevelopmentdrug discoveryemerging infectionspartnerships

Identifiers

PMID27325914
PMCPMC4912138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.